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We used ﬂow cytometry to analyze the cell cycle, DNA damage, and apoptosis in hematopoietic subsets in MDS marrow. Subsets
were assigned using CD45, side scatter, CD34, and CD71. Cell cycle fractions were analyzed using DRAQ 5 (DNA content) and
MPM-2 (mitoses). DNA damage was assessed using p-H2A.X, and apoptosis using Annexin V. Compared to controls, MDS
patients demonstrated no increased mitoses in erythroid, myeloid, or CD34+ cells. Myeloid progenitors demonstrated increased
G2 cells, which with no increased mitoses suggested delayed passage through G2. Myeloid progenitors demonstrated increased
p-H2A.X, consistent with DNA damage causing this delay. Annexin V reactivity was equivalent in MDS and controls. Results for
each parameter varied among hematopoietic compartments, demonstrating the need to analyze compartments separately. Our
results suggest that peripheral cytopenias in MDS are due to delayed cell cycle passage of marrow progenitors and that this delayed
passage and leukemic progression derive from excessive DNA damage.
1.Introduction
Myelodysplastic syndrome (MDS) is characterized by life-
threatening peripheral blood cytopenias and a propensity
to progress to acute myeloid leukemia (AML). Pathogenetic
explanations for both characteristics remain elusive. MDS
is a serious health problem, especially in the expanding
elderly population, where incidence approaches 80 cases per
100,000 population per year [1–5]. There is no eﬀective
curative strategy for MDS in elderly patients, and in younger
patients curative treatment consists of allogeneic stem cell
transplantation, which is expensive with associated mor-
bidity and mortality [6–8]. A current pathogenetic model
of MDS is hyperproliferation of marrow progenitors but
poor production of circulating cells due to excessive in vivo
apoptosis; however, this model is not supported by the
absence of hyperuricemia as a deﬁning characteristic of the
diseaseandfails toexplainthepropensityofMDStoprogress
to AML. An alternative model is that MDS is inherently a
mutatorphenotypecharacterized byincreasedDNAdamage,
that causing impaired cell cycling, failure of production
of peripheral blood cells, and leukemic transformation.
Improved treatment strategies for MDS require clariﬁcation
of its pathogenesis. To investigate these issues we used multi-
parametric ﬂowcytometrytoanalyze thecellcycle,including
mitotic events, DNA damage, and apoptosis in individual
hematopoietic precursor compartments in marrow samples
from patients with MDS.
2.Methods
2.1. Patients. MDS patients receiving no current treatment
werestudied.DiagnosisofMDSwasbasedonreviewbythree
observers of peripheral blood and marrow morphology,
clinical history, laboratory data, and cytogenetics. Diagnoses2 Bone Marrow Research
andclassiﬁcationwerebasedonpublishedrecommendations
andwereblindedtostudyresults[9–11].Patientsundergoing
elective orthopedic procedures with no marrow-based dis-
ease were used as controls.
2.2. Samples. MDS samples were collected from marrow
aspirates performed for routine clinical purposes. Controls
were obtained at the time of surgical insertion of orthopedic
implants. After collection, samples were diluted 1:1 with
RPMI. Samples were analyzed at 2–5 hours after procure-
ment(mean 3hours). Controls samplesused forFigures1, 3,
and 4 were obtained from patients with uninvolved marrow
undergoing marrow staging for a solid tumor.
2.3. Flow Cytometry. Following Ficoll-Hypaque isolation of
nucleated marrow cells, samples were assessed for CD45,
CD34, and CD71 surface antigen density, log side scatter,
DNA content (DRAQ5), mitotic index (reactivity with
MPM-2, a monoclonal antibody against a phosphorylated
epitope found on several proteins, including DNA topoiso-
merase II, cdc25,and Ki-67,phosphorylation being a marker
of passage through mitosis), phosphorylation of histone
H2A.X at serine 139 (p-H2A.X reactivity, a marker of DNA
double-strand breaks), and Annexin V binding (marker of
programmed cell death), using an FC500(Beckman-Coulter,
Fullerton,Calif)ﬂowcytometer[12–14].Majormarrowsub-
populations (myeloid, erythroid, CD34+, lymphoid) were
distinguished using CD45, side scatter, CD34, and CD71.
Antibodies to CD45, CD34, and CD71 were purchased from
Beckman-Coulter; MPM-2 from Dako (Carpinteria, Calif),
p-H2A.X from Cell Signaling Technologies (Danvers, Mass),
Annexin V from Invitrogen (Carlsbad, Calif), and DRAQ5
from Apotech (San Diego, Calif).
2.4. Identiﬁcation of Marrow Populations. DRAQ5 uptake
was used to select nucleated cells. Hematopoietic CD34+,
lymphoid, myeloid, and erythroid cell populations were
then discriminated by CD45/side scatter [15] coupled with
secondary gating on CD34 and CD71 surface antigen
expression. Criteria for subpopulation identiﬁcation were
nucleated erythroid lineage (CD71+/CD45-neg/low side
scatter), myeloid lineage (moderate CD45+/high side scat-
ter), stem cells (CD34+/moderate CD45+/low side scatter),
and lymphoid lineage (CD34-neg/CD71-neg/CD45++/low
side scatter) [15].
2.5. Cell Cycle Analysis. DRAQ5 staining was used for DNA
contentanalysis of cell cyclefractions (G0/G1, S,and G2/M),
allowing cell cycle fraction analysis in each major marrow
subpopulation using CD45, side scatter, CD34, and CD71
as described [13, 15–18]. DRAQ5 does not require ﬁxation
and membrane permeabilization for DNA assessment. Cell
cycle fraction expression of p-H2A.X and MPM-2 in each
major marrow subpopulation was achievedusing cell surface
marker staining (CD45, CD34, CD71), followed by ﬁxa-
tion/permeabilization of the cells in PermiFlow (InVirion,
Oak Brook, Ill), followed by intracellular antigen (p-H2A.X
and MPM-2) and DRAQ5 staining [19]. Cell cycle fraction
expression of Annexin V in each major marrow subpopu-
lation was achieved by combining Annexin V reactivity with
CD45,sidescatter,CD71,CD34,andDNAcontent(DRAQ5)
in an unﬁxed state in the presence of HBSS (Mediatech, Inc.
Herndon, Va).
2.6. Data Acquisition and Analysis. Each cytometry ﬁle con-
tained 250,000 total events. Primary gating and fractional
analysis was performed using WinList 5.0 software (Ver-
ity Software Topsham, Me) with DDE links of each cell
population to ModFit LT 3.0 (Verity Software) for cell
cycle modeling. The analysis results of each population
were ported into Microsoft Excel (Redmond, Wash) for
additional analysis. For p-H2A.X reactivity, positive controls
were marrows challenged with nitrogen mustard to induce
DNA damage. For Annexin V reactivity, negative controls
were based on measurements in Ca++,M g ++ free media, as
these ions are necessary for Annexin V reactivity. Analyses
w e r eb l i n d e dt oc l i n i c a lr e s u l t s .
2.7.Institutional ReviewBoard:ReviewandApproval. Studies
were reviewed and approved by the Vanderbilt University
Institutional Review Board.
2.8. Statistical Analysis. For each cell type the proportions of
cells from each patient in each phase of the cell cycle were
analyzed using Hotelling’s T-test. This multivariate analysis
tests the null hypothesis that the proportion of cells in each
phase of the cell cycle is the same in MDS and orthopedic
control patients. When this test was signiﬁcant, we further
testedwhethertheproportionsofcellsineachcellcyclephase
were the same in MDS and orthopedic control patients. We
used independent t-tests with unequal variance for these
comparisons. Following Fisher’s protected least signiﬁcant
diﬀerence approach, we did not adjust these univariate tests
for multiple comparisons.
Diﬀerences in expression of p-H2A.X and Annexin V
between MDS and control subjects were assessed using the
Wilcoxon rank sum test.
3.Results
3.1. Demographic and Diagnostic Data. Patients’ (n = 19)
demographic and clinical lab data (Table 1) are unremark-
able for MDS patients. The median age of patients was 58.5
years (range 5–82 years), with a male to female ratio of
1.4:1. Mean patient hemoglobin, hematocrit, platelet count,
and white blood cell count all diﬀered signiﬁcantly from
control values. MDS patients had intermediate- (refractory
cytopenia with multilineage dysplasia, RCMD, n = 9; or
RCMD with ringed sideroblasts, RCMD-RS, n = 1) to high-
grade (refractory anemia with excess blasts-1, RAEB-1, n =
2; or RAEB-2, n = 5) disease (WHO) [9]. Two patients
(including the single treatment-related case) had marrow
reticulin ﬁbrosis, precluding precise evaluation of dysplasia
and blast percentage. Both had pancytopenia and were not
low-gradeMDS.IPSSscoreswereLow(n = 3),Int-1(n = 6),
Int-2 (n = 7), or High (n = 3) [11]. The control groupBone Marrow Research 3
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Figure 1: Multiparametric ﬂow cytometry analysis of representative control bone marrow. Multiparametric ﬂow cytometry analysis of
control bone marrow displaying major subsets of cells based on SSC, CD45 density, CD34 (not shown), and CD71 (not shown) (center
panel). DNA content (DRAQ5) analysis is plotted versus number of cells or versus MPM2 signal intensity for each of the gated populations
(large arrows). The lymphocyte population (orange) (high CD45, low SSC) (upper left) contains predominantly cells with G1 cell cycle
phase DNA content and no mitoses. The stem cell (blue) (intermediate CD45 and SSC, CD34+) (lower left), myeloid (green) (intermediate
CD45, high SSC) (upper right), and nucleated erythroid (red) (intermediate SSC, low CD45, CD71+, DRAQ V+) (lower right) populations
contain cells with G0/G1, S, and G2/M DNA content, and cells that mark for mitosis (M) (elevated MPM2 signal in cells with G2/M DNA
content).
of patients were demographically similar to MDS patients
(median age 61.3, range 45–92 years), with a male to female
ratio of 0.7:1, showing a slight bias of controls to female
patients.
3.2. Cell Cycle Analysis. The approach for collection of cell
cyclefraction resultsfor each hematopoieticlineage is shown
for a representative control patient in Figure 1.
CD45 versus side scatter plots produce clusters that
represent major lineages [15]. We used CD34 positivity to
identify immature cells(blue)and CD71positivity for nucle-
ated erythroid precursors (red). CD45 versus side scatter
alone identiﬁed lymphocytes (orange) and myeloid precur-
sors (green). DRAQ5 uptake allowed restriction of analysis
to nucleated cells and provided cell cycle phase fractions
based on DNA content (insets). MPM-2 reactivity was used
toidentifymitotic cells. Asdemonstrated in Figure 1,b yboth
the ratio of S and G2 to G0/G1 (insets) and the fraction
of mitotic cells (arrows), diﬀerent lineage sets have diﬀerent
phase fraction proﬁles, suggesting that they cycle at diﬀerent
rates, following the order erythroid > myeloid > CD34+>
lymphoid from most rapidly proliferating to slowest. Mean
results and ranges for cell cycle distribution in the control set
are summarized in Table 2.
Arepresentative MDSpatient is shown in Figure 2.M e a n
results and ranges for cell cycle distribution in MDS patients
are summarized in Table 2.
The proportion of cells in each cell cycle phase was com-
pared betweencase and control subjects foreach hematopoi-
etic cell type. These proportions were not signiﬁcantly
diﬀerent for either the erythroid progenitors or CD34+ cells.
However, theydid diﬀersigniﬁcantlyformyeloidprogenitors
(P = .002). Among MDS patients the average proportion
of myeloid cells in G2 was 4.3% versus 1.6% in control
patients (P = .004; see Table 1). Notably, mitotic events
were not signiﬁcantly elevated in any MDS patient cell group
(erythroid, myeloid, or CD34+) compared to controls.
3.3. H2A.X Phosphorylation. Because of our ﬁnding of an
elevated G2 fraction in myeloid cells in MDS, we evaluated4 Bone Marrow Research
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Figure 2: Multiparametric ﬂow cytometry analysis of representative MDS bone marrow. Multiparametric ﬂow cytometry analysis of a
representative MDS case using the same analytical scheme and color coding as described in Figure 1. G-M progenitors (green) contain an
accumulation of cells in G2 with diminished mitosis (M) compared to G-M progenitors in the control marrow (Figure 1). In this case
erythroid precursors (red) and CD34+ stem cells (blue) exhibit relatively normal cell cycle parameters (DNA content, mitotic cells) versus
the control sample (Figure 1).
phosphorylation of histone H2A.X at serine 139 (p-H2A.X),
a marker of DNA double-strand breaks (DSBs), to explore
the possibility of excessive DNA damage in MDS cells.
Representative displays of p-H2A.X reactivity versus DNA
content in a control and an MDS patient are shown in
Figure 3, with p-H2A.X reactivity within each cell subtype
summarized in Table 3 [20, 21]. While there is heterogeneity
among samples (see ranges, Table 3), we detected a 5-fold
increase ofp-H2A.Xreactivity intheerythroidcompartment
in MDS versus controls that may indicate an increase but did
not rise to statistical signiﬁcance (P = .20). A more marked
14-fold increase in myeloid progenitors versus controls was
signiﬁcant (P = .001). CD34+ cells showed no signiﬁcant
diﬀerence of MDS samples compared to controls.
3.4. Annexin V. Since increased apoptosis has been associ-
ated with MDS in some reports, [22] we evaluated apop-
tosis using Annexin V binding in each cell compartment.
Representative displays of Annexin V reactivity versus DNA
content in a control and an MDS patient are shown in
Figure 4, with Annexin V reactivity within each cell sub-
type summarized in Table 3. There is heterogeneity among
hematopoietic cell subsets, but we did not identify any
signiﬁcant increaseintheproportionofapoptoticcellsinany
hematopoietic cell subset in MDS compared to the control
population.
3.5.Cell Cycle-Related H2A.XPhosphorylation and Annexin V
Reactivity. DNA fragmentation during apoptosis can result
in H2A.X phosphorylation, although usually the level of
phosphorylation is much greater than that measured for
DNA damage [20, 21]. We analyzed the relationship of
H2A.X phosphorylation versus Annexin V binding. Assess-
ment of H2A.X phosphorylation versus DNA content,
illustrated in representative control and MDS samples in
Figure 3, allowed analysis of p-H2A.X reactivity by cell
cycle compartment (G0/G1, post-G1) in erythroid and
myeloid progenitors using combinations of p-H2A.X reac-
tivity, side scatter, CD45 antigen density, and DNA con-
tent. Control erythroid progenitors demonstrate minimal
p-H2A.X reactivity, while MDS samples demonstrate p-
H2A.X reactivity, predominantly in G0/G1 but also in S
and G2. Control myeloid progenitors demonstrate modest
p-H2A.X reactivity, predominantly in G0/G1, while MDS
samples demonstrate marked reactivity in G0/G1, S, and
G2. Similar cell cycle analyses for Annexin V are illustratedBone Marrow Research 5
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Figure 3:Comparative γH2A.X ﬁndings in representative control versus MDS marrow.Multiparametric ﬂowcytometry analysisof γH2A.X
density and DRAQ V in G-M and erythroid progenitors in control (top) and MDS (bottom) marrows.Major subsets of cells were identiﬁed
as described in Figure 1 for control (top left) and MDS (bottom left). G-M progenitor cells from control (top middle) and MDS (bottom
middle) anderythroid progenitorcells fromcontrol(topright)andMDS(bottomright)wereanalyzedforDNAandγH2AX. Thehorizontal
bars were used to determine levels of γH2AX density in MDS above the control marrow in both G-M and erythroid progenitors.
in representative control and MDS samples in Figure 4.I n
contrast to p-H2A.X reactivity, Annexin V demonstrates
similar cell cycle distribution patterns in MDS and control
samples,withpredominantexpression inG0/G1.Theseanal-
yses allowed comparison ofthe interrelationship of p-H2A.X
andAnnexin Vreactivity incellcyclefractions. p-H2A.Xand
Annexin V reactivity correlate signiﬁcantly only in G0/G1 in
myeloid progenitors (P = .05); post-G1 myeloid progenitor
and both G0/G1 and post-G1 erythroid progenitor p-H2A.X
and Annexin V reactivities demonstrate no correlation.
These results suggest that at least a major proportion of
H2A.X phosphorylation at serine 139 in MDS is unrelated
to apoptosis, neither a result of DNA fragmentation during
apoptosis nor associated with initiation of apoptosis.
4.Discussion
MDS is characterized by life-threatening peripheral cytope-
nias and a tendency to progress to a subset of AML that
is diﬃcult to treat. Improvements in treatment approaches
f o rM D Sa n dt h i ss u b s e to fA M Lm a yr e q u i r ec l a r i ﬁ c a t i o n
of the pathogenesis of MDS. A current pathogenetic model
characterizes MDS as a combination of hyperproliferation
of marrow progenitors with excessive apoptosis, leading to
poor production of peripheral blood cells. An alternative
model characterizes MDSas a mutatorphenotypewith DNA
damage as the direct cause of both peripheral cytopenias due
to impairment of cell cycling of hematopoietic progenitors
and leukemic progression. To evaluate these possibilities,
we analyzed marrow samples from MDS patients using
multiparametric ﬂow cytometry techniques that allowed
analysis of the cell cycle, including mitotic activity, in
individual hematopoietic precursor compartments, and
additional analysis of DNA damage and apoptosis in both
individual hematopoietic precursor compartments and cell
cycle subsets. Of particular note, neither erythroid, myeloid,
nor CD34+ cells in MDS patients exhibited signiﬁcantly
increasedmitoticeventsversuscontrols,indicatingthatMDS
marrow is not hyperproliferative. These results call into
question previous interpretations of DNA content [23–25]6 Bone Marrow Research
Table 1: MDS patient demographic and diagnostic data.
Age Sex Hct Plts ANC Blast % Cytogenetics Diagnosis IPSS
PB MRW
1 58 M 38 66 1.7 0 0 t(1;7) Hypocellular RCMD Int-2
2 72 M 24 91 5.5 0 4 (−5, −7) RCMD Int-2
3 75 F 25 13 4.3 0 0.5 1 abnormal cell RCMD-RS Int-1
4 59 M 32 134 0.8 0 13 (20q-, −5, +14) RAEB-2 High
5 62 M 28 35 0.9 0 <5( −7) 2◦ MDS, retic ﬁbr Int-2
65 F2 44 90 . 9 0<0.5 46XX RCMD Int-1
7 59 M 26 12 1.8 0 <0.5 46XY RCMD Int-1
8 82 F 24 27 1.1 0 <5 no metaphases MDS with retic ﬁbr Int-1
9 65 F 38 97 2.1 0 1.5 (−5) RCMD Int-1
10 52 F 21 366 3.5 0 3.5 46XX RCMD Low
11 63 M 30 20 0.8 4 11 (−5, −7), other RAEB-2 High
12 65 F 26 23 0.7 0 6 46XX RAEB-1 Int-1
13 67 F 24 13 0.03 0 8 (−5, 20q-) RAEB-1 Int-2
14 58 M 26 66 0.1 0 12 (20q-) RAEB-2 Int-2
15 64 M 27 51 0.2 0 11 t(3; 21) RAEB-2 High
16 38 F 35 208 0.7 0 0.5 46XX RCMD Low
17 58 M 27 15 0.05 0 11 (20q-) RAEB-2 Int-2
18 20 M 37 23 0.2 0 <0.5 (−7) (familial) RCMD Int-2
19 81 M 30 178 3.5 0 1.5 46XY RCMD Low
Hct: % hematocrit; Plts: platelets (thousands/microliter);ANC: absolute neutrophil count (thousands/microliter);PB: peripheral blood; MRW: marrow; retic
ﬁbr: reticulin ﬁbrosis; RCMD: refractory cytopenia with multilineage dysplasia; RAEB: refractory anemia with excess blasts; IPSS: International Prognostic
Scoring Systemfor MDS; Int: intermediate.
Table 2: Cell cycle analysis of marrow samples.
S (%) G2 (%) M (%)
Controls MDS Controls MDS Controls MDS
nRBC 27.9 (16.2–41.9) 31.2 (12.8–56.4) 4.7 (2.1–8.2) 6.3 (1.1–17.0) 1.1 (0.5–1.6) 1.0 (0.01–3.6)
Myeloid 16.0 (6.7–28.1) 17.16 (7.8–32.1) 1.6 (0.0–3.3) 4.3 (0.2–11.5) 0.32 (0.2–0.6) 0.45 (0.0–1.1)
CD34+ 13.5∗ (7.4–22.9) 10.9∗ (2.0–16.0) ∗∗ 0.6 (0.2–1.1) 0.8 (0.1–2.3)
Controls (n = 20), MDS (n = 19).
Cell populations discriminated by CD45, SS, CD71, and CD34.
DNA content assessedusing DRAQ5; mitoses assessedusing MPM-2.
Results expressed as mean (%) positive (range).
∗Because of infrequent stem cell events, S and G2 are combined as post-G1 for stem cells.
Table 3: p-H2A.X and Annexin V reactivity in marrow cells.
p-H2A.X (%) Annexin V (%)
Controls
(n = 20)
MDS
(n = 17)
Controls
(n = 20)
MDS
(n = 17)
nRBC 1.5
(0.4–3.7)
8.0
(0.1–49.9)
19.4
(3.1–54.6)
12.3
(2.2–55.3)
Myeloid 1.1
(0.1–4.6)
15.9
(0.2–51.0)
16.4
(4.0–58.0)
24.2
(1.2–89.7)
CD34+ 1.7
(0.2–4.9)
1.7
(0.0–5.1)
11.6
(3.8–26.5)
11.9
(1.9–61.5)
Cell populations discriminated by CD45, SS, CD71, and CD34.
Results expressed as mean (%) positive (range).
and in vivo DNA labeling [26–29] studies as indicative of
increased proliferation of marrow cells in MDS. As our
data show, a ﬁnding of increased cells in S or G2 by DNA
content without simultaneous analysis of mitotic activity is
not deﬁnitive evidence of proliferation. We also demonstrate
unexpected heterogeneity in cell cycle fractions in diﬀerent
hematopoietic progenitor subsets in both controls and MDS
samples, with erythroid progenitors showing a 1.5- to
2-fold increase in S and G2 events versus myeloid progen-
itors. Thus, failure to compensate for erythroid hyperplasia,
a commonﬁnding in MDS,ininterpreting DNAcontentand
labeling data could result in misinterpretation of results as
hyperproliferation, rather than normal proliferation with an
expanded erythroid compartment. Other factors may also
be contributory to variance of our results versus in vivo
DNA labeling studies. Incorporation of labeled nucleotides
in DNA is not uniquely speciﬁc for DNA synthesis (e.g.,
it may occur with DNA repair, and our ﬁndings suggest
increased DNA damage in MDS), and in vivo DNA labelingBone Marrow Research 7
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Figure 4: Comparative Annexin V ﬁndings in representative control versus MDS marrow. Multiparametric ﬂow cytometry analysis of
Annexin V positivity and DRAQ V in G-M and erythroid progenitors in control (top) and MDS (bottom) marrows. Major subsets of cells
were identiﬁed as described in Figure 1 for control (top left) and MDS (bottom left). G-M progenitor cells from control (top middle) and
MDS (bottom middle) and erythroid progenitor cells from control (top right) and MDS (bottom right) were analyzed for DRAQ V and
Annexin V. The horizontal bars were used to determine levels of Annexin V positivity in MDS above the control marrow in both G-M and
erythroid progenitors.
studies can include no normal controls, as the agents are
mutagenic.
Under normal physiologic control in mammalian cells,
S, G2, and M should maintain constant ratios. Our demon-
stration of a signiﬁcant increase in the G2 compartment in
myeloid precursors in MDS patients versus controls, with
no increase in mitotic events, indicates aberrant cell cycle
progression with delayed G2 transit, not proliferation. Mean
G2 cells were also increased above controls in erythroid
precursors, but the diﬀerence was not signiﬁcant. A possible
explanation for delayed G2 transit is DNA damage. To
evaluate this possibility, we analyzed MDS samples for
histone H2A.X phosphorylation at serine 139 (p-H2A.X),
this phosphorylation being mediated by ATM in response to
double-strand DNA breaks [20, 21, 30, 31]. We observed a
highly signiﬁcant 14-fold elevation of p-H2A.X in myeloid
precursors in MDS samples and a 5-fold (not signiﬁcant)
elevationinerythroidprecursors. These ﬁndings suggestthat
hematopoietic precursors in MDS have high levels of DNA
damage, a possible explanation forboth thedelayedcell cycle
transit that our data suggest and the preleukemic phenotype
of MDS. Horibe et al. have recently reported similar results,
using immunohistochemistry to demonstrate activation of
ATM and phosphorylation of its substrate H2A.X in marrow
samples from MDS patients, with little activity in control
marrows. In addition, their observation of activation of the
checkpoint genes Chk2 and p53 in MDS is consistent with
the delayed G2 transit that our data suggest [32].
Using Annexin V reactivity we were unable to demon-
strate the increased apoptosis reported in MDS marrow by
others (reviewed in [33]). An explanation for this disparity
is uncertain. We did support marrow cell viability ex vivo
with RPMI, coupled with rapid processing and analysis. We
found no correlation of p-H2A.X versus Annexin V in most
settings. We did note this correlation in G0/G1 in myeloid
progenitors. DNA degradation during late apoptosis may
result in marked phosphorylation of H2A.X (which we did
not detect)[20], while DNAdamage (with associated H2A.X8 Bone Marrow Research
phosphorylation) can trigger apoptosis. It is possible that the
correlation we observed in this limited setting is due to the
latter.
Our ﬁnding of normal mitotic rates in MDS samples
is consistent with our Annexin V results, suggesting that
our results reﬂect more accurately the in vivo physiologic
state in MDS. It would be kinetically impossible to maintain
the typical hypercellular marrow in MDS with increased
apoptosis but no increase in mitotic activity. It should be
noted that assays of apoptosis are performed ex vivo.
Production of uric acid is an in vivo surrogate for cell death;
the routine absence of hyperuricemia in MDS is inconsistent
with increased in vivo apoptosis. Our ﬁnding of no apoptotic
response in cells in G2 despite evidence of increased DNA
damage suggests an alternative interpretation of data in
MDS, namely that in MDS there may be a failure in vivo
to trigger eﬀective apoptosis in response to DNA damage.
If so, cells with unrepaired DNA damage could accumulate
in marrow, resulting in hypercellularity. With the additional
stress of aspiration, these cells would proceed to apoptosis,
resulting in a false impression of excessive in vivo apoptosis.
Multiparametric ﬂow cytometry was crucial for perfor-
mance of these studies, allowing simultaneous quantitative
analysis of cell cycle and other parameters in electronically
segregated subpopulations of marrow cells. Use of MPM-2,
with direct quantitation of mitoses, gave a more complete
assessment of the cell cycle than DNA content alone [12–
14]. Use of DRAQ5 for DNA content analysis allowed
simultaneous analysis with other parameters in segregated
hematopoietic subpopulations, which demonstrated unex-
pectedheterogeneity ofvirtually all parameterstested among
diﬀerent hematopoietic subpopulations. Our results cast
doubt on the interpretability of whole marrow analyses of
these parameters in previously reported studies and allowed
demonstration of abnormal cell cycle progression in one
hematopoieticsubset.Wedemonstrateddiﬀerencesinresults
for some parameters (p-H2A.X, Annexin V) in diﬀerent
cell cycle fractions and that these diﬀerences also varied
in diﬀering hematopoietic progenitor subpopulations. This
complexity would be diﬃcult to demonstrate with any other
available analytical technology.
5.Conclusions
We demonstrate that MDS is not hyperproliferative, that
MDS may have an aberrant delay in the cell cycle, that MDS
has evidenceofunrepaired DNAdamage,and that MDS may
have a diminished in vivo apoptotic response to that damage.
These observations are in contradistinction to a widely held
model of MDS as a hyperproliferative process with excessive
in vivo programmed cell death. We hypothesize that DNA
damage with aberrant cell cycling may contribute directly
to both the marrow failure of MDS and its preleukemic
phenotype.
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